Boston Scientific(US:BSX) Globenewswire·2026-03-22 20:00Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding its financial outlook and market competition [1][4]. Group 1: Class Action Details - The class action lawsuit is titled Troike v. Boston Scientific Corporation, and it involves purchasers of Boston Scientific common stock from July 23, 2025, to February 3, 2026 [1]. - Investors have until May 4, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Boston Scientific and its executives misrepresented the company's revenue outlook and downplayed risks from market competition [4]. Group 2: Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, showing a GAAP net income of $672 million or $0.45 per share for Q4 2025, compared to $566 million or $0.38 per share a year ago [5]. - For the full year 2025, the company reported a GAAP net income of $2.898 billion or $1.94 per share, up from $1.853 billion or $1.25 per share the previous year [5]. - The adjusted EPS for Q4 2025 was $0.80, compared to $0.70 a year ago, and for the full year, it was $3.06, compared to $2.51 a year ago [5]. - Following the financial results announcement, Boston Scientific's stock price fell more than 17% [5]. Group 3: Company Background - Boston Scientific develops, manufactures, and markets medical devices for various interventional medical specialties globally [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 [7].